Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (Nasdaq/NYSE: REGN) is a Biotechnology company operating within the Health Care sector of the US equity market.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

The company reports trailing twelve-month revenue of $1.51B and net income of $727.20M.

Key metrics include a return on equity of 2.3%, a debt-to-equity ratio of 0.30.

Use FINOTAUR to track REGN's price action, review fundamentals, and stay current with company news — all in one research dashboard.